Literature DB >> 12115317

Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor.

Mark S Litwin1, Deborah P Lubeck, G Mark Spitalny, James M Henning, Peter R Carroll.   

Abstract

BACKGROUND: The current study was conducted to assess posttreatment changes in the mental components of health related quality of life in prostate carcinoma patients during the two years following diagnosis and management with radical prostatectomy, pelvic irradiation, or watchful waiting.
METHODS: The authors studied the mental domains of general health related quality of life in 452 men recently diagnosed with early stage prostate carcinoma and treated with radical prostatectomy, pelvic radiation, or watchful waiting. Outcomes were assessed with the RAND 36-Item Health Survey, a validated health-related quality of life instrument that includes four mental domains. To minimize the influence of potentially confounding factors, the authors adjusted for age, comorbidity, prostate specific antigen (PSA) at diagnosis, and biopsy Gleason score. All subjects were drawn from CaPSURE, a national, longitudinal cohort.
RESULTS: By 6-12 months after treatment, the active treatment groups began to show differences in mental health and vitality. By 15 months, surgery and radiation patients scored differently in all four mental domains. Over time, the gaps between mental domain scores grew wider among the treatment groups, with surgery patients performing the best, radiation patients performing the worst, and watchful waiting patients falling in between.
CONCLUSIONS: The mental health profiles differ for patients undergoing surgery, radiation, or watchful waiting for early stage prostate carcinoma. Men with more serious disease, as evidenced by higher PSA levels or more aggressive histology, tended to worry more about it. Older men performed better, while sicker men performed worse, even though the older men tended to be sicker. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Year:  2002        PMID: 12115317     DOI: 10.1002/cncr.10651

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  Active surveillance for low-risk prostate cancer: an update.

Authors:  Nathan Lawrentschuk; Laurence Klotz
Journal:  Nat Rev Urol       Date:  2011-04-26       Impact factor: 14.432

Review 2.  Global registries for measuring pharmacoeconomic and quality-of-life outcomes: focus on design and data collection, analysis and interpretation.

Authors:  Lisa Kennedy; Ann-Marie Craig
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.

Authors:  Yoichi Arai; Hideyuki Akaza; Takashi Deguchi; Masato Fujisawa; Mikio Hayashi; Yoshihiko Hirao; Hiroshi Kanetake; Seiji Naito; Mikio Namiki; Masaaki Tachibana; Michiyuki Usami; Yasuo Ohashi
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-20       Impact factor: 4.553

4.  Focal therapy for localized prostate cancer -choosing the middle ground.

Authors:  Uri Lindner; John Trachtenberg
Journal:  Can Urol Assoc J       Date:  2009-08       Impact factor: 1.862

5.  The Effects of Radical Prostatectomy on Gay and Bisexual Men's Mental Health, Sexual Identity and Relationships: Qualitative Results from the Restore Study.

Authors:  B R Simon Rosser; Benjamin Capistrant; Beatriz Torres; Badrinath Konety; Enyinnaya Merengwa; Darryl Mitteldorf; William West
Journal:  Sex Relation Ther       Date:  2016-09-09

Review 6.  Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer.

Authors:  Christopher J Welty; Matthew R Cooperberg; Peter R Carroll
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

Review 7.  Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.

Authors:  Kyle O Rove; E David Crawford
Journal:  World J Urol       Date:  2011-11-25       Impact factor: 4.226

8.  Quality of life in men undergoing active surveillance for localized prostate cancer.

Authors:  Jonathan Bergman; Mark S Litwin
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

9.  The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer.

Authors:  Hung-Jui Tan; Leonard S Marks; Michael A Hoyt; Lorna Kwan; Christopher P Filson; Malu Macairan; Patricia Lieu; Mark S Litwin; Annette L Stanton
Journal:  J Urol       Date:  2016-02-09       Impact factor: 7.450

10.  Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Authors:  Julia H Hayes; Daniel A Ollendorf; Steven D Pearson; Michael J Barry; Philip W Kantoff; Susan T Stewart; Vibha Bhatnagar; Christopher J Sweeney; James E Stahl; Pamela M McMahon
Journal:  JAMA       Date:  2010-12-01       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.